Features | Partner Sites | Information | LinkXpress
Sign In

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



view channel
Image: Multimodal CT images obtained 2 hours 18 minutes after symptom onset in an 87-year-old woman with an NIH Stroke Scale of 15 and left hemisphere symptoms (Photo courtesy of Radiology 2015:257;2;510-520, and RSNA 2015).

Faster and Simpler Treatment for Stroke Patients Using Multiphase CT

The results of a new study show that multiphase Computed Tomography (CT) angiography brain-imaging could enable clinicians to treat Acute Ischemic Stroke (AIS) patients faster, and better, potentially saving lives.... Read more


view channel

Study Shows Steep Rise in the Use of MRI Scans Before Breast Cancer Surgery

The results of a new study have shown an eightfold rise in the use of Magnetic Resonance Imaging (MRI) scans before breast cancer surgery in the Canadian province of Ontario between 2003 and 2012. Guidelines on the use of MRI scans before surgery are inconsistent, the study showed, and the increased use of MRI was characteristic... Read more

General/Advanced Imaging

view channel

Leading Vendor to Implement and Install Enterprise Imaging Platform for UK NHS

An agreement has been announced by a leading imaging platform provider for the implementation of the first Enterprise Imaging platform, part of a long-term agreement for the management of imaging data, for the UK City Hospitals Sunderland NHS Foundation Trust. The agreement covers the capture, storage, and exchange of... Read more

Imaging IT

view channel

Carestream Updates Healthcare IT Platform

Carestream has released updates for an advanced Internet Technology (IT) healthcare platform at the Röntgenveckan Radiology congress in Malmo (Sweden). The IT platform facilitates collaboration by enabling sharing of critical patient information such as Radiology images, videos, reports, and services with groups outside... Read more

Industry News

view channel

New Distribution and Commercialization Agreement for Medical Imaging Contrast Agent in China

China’s second largest pharmaceutical distribution group and an international medical imaging pharmaceutical group have announced an agreement for the distribution and commercialization of Lipiodol Ultra-Fluid, from September 2015. Lipiodol Ultra-Fluid is used in interventional radiology procedures as a contrast agent,... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.